Pelechas Eleftherios, Memi Tereza, Voulgari Paraskevi V, Drosos Alexandros A
Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece.
Rheumatol Ther. 2017 Dec;4(2):509-513. doi: 10.1007/s40744-017-0084-0. Epub 2017 Oct 11.
Psoriatic arthritis (PsA) is a unique inflammatory arthritis due to the fact that patients have to deal not only with pain but also with their skin appearance, which may have a detrimental effect on their everyday lives and psychology. Treating a patient with PsA, improving both the musculoskeletal and skin symptoms is a challenge for the clinical rheumatologist. In this case, we present a patient of recalcitrant PsA to tumor necrosis factor inhibitors (TNFi) who had an exceptional improvement after administration of the interleukin-17A inhibitor (IL-17Ai) secukinumab.
银屑病关节炎（PsA）是一种独特的炎性关节炎，因为患者不仅要应对疼痛，还要面对皮肤外观问题，这可能会对他们的日常生活和心理产生不利影响。对于临床风湿病学家来说，治疗银屑病关节炎患者并改善其肌肉骨骼和皮肤症状是一项挑战。在此，我们报告一例对肿瘤坏死因子抑制剂（TNFi）耐药的银屑病关节炎患者，在使用白细胞介素-17A抑制剂（IL-17Ai）司库奇尤单抗后有显著改善。
